Committee ok's Schering-Plough's sugammadex

An FDA committee has unanimously recommended Schering-Plough's sugammadex for approval. The drug, which is being developed to reverse the effects of anesthesia used during surgery, allows doctors to reverse the depth of a patient's muscle relaxation within minutes. The FDA usually follows the committee's recommendation. The drug gained priority review in January.

Schering gained sugammadex in its massive $14.4 billion buyout of Organon one year ago. Sugammadex will be sold under the name Bridion if approved.

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."